In spite of the Affordable Care Act's contraceptive coverage guarantee, there have been some obstacles in ensuring that privately insured women do not encounter out-of-pocket cost.
In spite of the Affordable Care Act (ACA)'s contraceptive coverage guarantee, there have been some obstacles in ensuring that privately insured women do not encounter out-of-pocket costs, according to a study published in JAMA.
The ACA guarantee says that privately-insured women must receive coverage for FDA-approved contraceptive methods and the included office visit, sterilization procedures, patient education and counseling, follow-up and management of effects, and removal. Not included are supplies without prescription, male contraceptive methods, out-of-network costs, and there are some plans that have received a reprieve.
In saving on out-of-pocket saving, the ACA has the potential to improve public health by reducing financial barriers to contraception and reduce unintended pregnancies and births, and by offering help to women who want to continue their educational and professional goals or better support themselves and their families.
There have been some issues, however, in enacting the ACA requirements and all their intended results. Some insurers have limited the types of contraceptives they cover by only paying for generic versions of oral contraceptives or excluding certain methods of contraception, such as the vaginal ring.
“The whole goal of the ACA is to provide access to needed health care,” Mary Politi, MD, co-author, said in a statement. “But there are numerous situations in which women are not receiving contraceptive services that they are entitled to under the law.”
In order to account for these situations a federal guideline released in May 2015 said that plans must cover at least one form of contraception, without cost sharing, in each of the 18 categories provided by the FDA. Additionally, plans must defer to clinician recommendations when necessary.
Problems with billing have also cropped up when patients have been incorrectly charged for costs that should have been covered by insurance, either through inappropriate insurance practices or through clinician mistakes when applying billing codes. More transparency in communication is then required so that patients know when they are being billed and for what, especially when it is out-of-network.
As such, it is not just the duty of the insurance company, but also of state regulators and healthcare professionals, to follow federal guidelines.
“Improved implementation could ensure that the contraceptive coverage guarantee fully meets its potential to improve women’s preventive care, including contraception,” said co-author Tessa Madden, MD. “We know that access to contraception without out-of-pocket costs reduces unintended pregnancies and births, which can have a great impact on the health of women and families.”
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More